Trial of Micafungin (FK463) in Combination With Liposomal Amphotericin B (AmBisome) for Aspergillosis

Inclusion Criteria * Have proven or probable systemic infection with Aspergillus species and have received no more than 96 hours of prior therapeutic doses of systemic antifungal therapy Exclusion Criteria * Has abnormal liver test parameters, e.g., AST or ALT \> 10 times upper limit of normal * Has allergic bronchopulmonary aspergillosis, aspergillomas, or with sinus aspergillosis or external otitis who do not have evidence of tissue invasion * Has life expectancy of less than five days